|
Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
Site
Search
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
Interferon-alpha-induced disorders of thyroid function. A
retrospective analysis of the literature and personal
experiences
Original: Interferon-alpha-induzierte Störungen der
Schilddrüsenfunktion. Eine retrospektive Analyse der Literatur
und eigener Erfahrungen.
Author: Weissel M; Templ E; Gisslinger H Address
Universitätsklinik für Innere Medizin III, Wien. Source
Acta Med Austriaca, 22: 1-2, 1995, 1-5
Abstract:
This paper tries to evaluate the importance of IFN-alpha induced
thyroid dysfunction. Based on our own experience and reported data
we present the results obtained in a total of 588 patients, in whom
thyroid function and thyroid antibody occurrence was monitored
during therapy with IFN-alpha: About 10% of these patients
developed thyroid dysfunction during IFN-alpha treatment. Half of
them reacted with hypothyroidism, 3% with hyperthyroidism and in 2%
a biphasic (hyperthyroidism followed by hypothyroidism) pattern of
reaction was observed. The frequency of these thyroid dysfunctions
was increased in female patients and in patients with preexisting
thyroid antibodies. The risk to develop thyroid dysfunction is
reduced to 7% in patients with no pretherapeutic thyroid
antibodies. The evolution of the thyroid ailment is variable and
therefore unpredictable. In many patients there is no need to stop
treatment with IFN-alpha nor to treat the thyroid dysfunction
specifically. IFN-alpha induced autoimmune-phenomena seem to be
etiologically important for the development of thyroid disease
during IFN-alpha. The reported data allow in our view some basic
recommendations for the clinician: thyroid function and thyroid
antibodies should be evaluated before the start of treatment with
IFN-alpha. During therapy with IFN-alpha these parameters should be
regularly (eg every 4 months) monitored. In patients with thyroid
autoantibodies or dysfunction already before IFN-alpha the control
intervals should not be longer than every two months.
Language of Publication German Unique Identifier
95373298
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|